{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:02:26Z","timestamp":1747108946016,"version":"3.40.5"},"reference-count":50,"publisher":"Media Sphere Publishing House","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Ann. Ophthal."],"published-print":{"date-parts":[[2025,5,12]]},"abstract":"<jats:p>The development of biological therapeutic agents has provided new opportunities for treating neovascular age-related macular degeneration (nAMD) using humanized monoclonal antibodies (mAbs) targeting vascular endothelial growth factor A (VEGF-A). The emergence of biosimilars of anti-VEGF agents can significantly improve treatment accessibility and its effectiveness by increasing patient adherence. The development of biosimilars involves comparative studies with the original drug to establish equivalence in physicochemical and biological properties, efficacy, and safety. Biosimilar development programs include extensive analytical and preclinical studies to compare structural and functional components with the original bioproduct, and clinical trials are conducted to prove bioequivalence and therapeutic equivalence. The process of development and registration of the biosimilars is strictly regulated and has no significant differences in Russia, the EU and the US. Currently, more than 10 biosimilars of ranibizumab have been approved worldwide, in Russia it is the drug Laxolan (AO GENERIUM). The introduction of a domestic biosimilar of ranibizumab into clinical practice allows reduction of the costs of retinal disease treatment while maintaining the efficacy and safety of antiangiogenic therapy.<\/jats:p>","DOI":"10.17116\/oftalma2025141021106","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:58:44Z","timestamp":1747051124000},"page":"106","source":"Crossref","is-referenced-by-count":0,"title":["Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology"],"prefix":"10.17116","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-4923","authenticated-orcid":false,"given":"A.A.","family":"Voskresenskaya","sequence":"first","affiliation":[{"name":"Cheboksary branch of the S.N. Fedorov National Medical Research Center \u201cMNTK \u201cEye Microsurgery\u201d","place":["Cheboksary, Russia"]},{"name":"Postgraduate Doctors Training Institute","place":["Cheboksary, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-3928","authenticated-orcid":false,"given":"M.B.","family":"Sarkizova","sequence":"additional","affiliation":[{"name":"S.N. Fedorov National Medical Research Center \u201cMNTK \u201cEye Microsurgery\u201d","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7614-628X","authenticated-orcid":false,"given":"N.S.","family":"Khodzhaev","sequence":"additional","affiliation":[{"name":"S.N. Fedorov National Medical Research Center \u201cMNTK \u201cEye Microsurgery\u201d","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-4467","authenticated-orcid":false,"given":"D.A.","family":"Kudlay","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]},{"name":"Lomonosov Moscow State University","place":["Moscow, Russia"]},{"name":"JSC GENERIUM","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-953X","authenticated-orcid":false,"given":"S.A.","family":"Kakunina","sequence":"additional","affiliation":[{"name":"S.N. Fedorov National Medical Research Center \u201cMNTK \u201cEye Microsurgery\u201d","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-8471","authenticated-orcid":false,"given":"A.Yu.","family":"Borozinets","sequence":"additional","affiliation":[{"name":"JSC GENERIUM","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3637-3645","authenticated-orcid":false,"given":"N.A.","family":"Pozdeyeva","sequence":"additional","affiliation":[{"name":"Cheboksary branch of the S.N. Fedorov National Medical Research Center \u201cMNTK \u201cEye Microsurgery\u201d","place":["Cheboksary, Russia"]},{"name":"Postgraduate Doctors Training Institute","place":["Cheboksary, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma2025141021106-1","unstructured":"Klinicheskie rekomendatsii. Vozrastnaya makulyarnaya degeneratsiya. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2021. Accessed 16.12.2024 (In Russ.). https:\/\/legalacts.ru\/doc\/klinicheskie-rekomendatsii-vozrastnaja-makuljarnaja-degeneratsija-utv-minzdravom-rossii"},{"key":"key-10.17116\/oftalma2025141021106-2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd005139.pub4"},{"key":"key-10.17116\/oftalma2025141021106-3","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2176218"},{"key":"key-10.17116\/oftalma2025141021106-4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.06.007"},{"key":"key-10.17116\/oftalma2025141021106-5","unstructured":"Pravila provedeniya issledovanii biologicheskikh lekarstvennykh sredstv Evraziiskogo ekonomicheskogo soyuza. Reshenie Soveta EEK ot 03.11.2016 No. 89. Accessed 16.12.2024 (In Russ.). https:\/\/www.alta.ru\/tamdoc\/16sr0089"},{"key":"key-10.17116\/oftalma2025141021106-6","unstructured":"EMA: Similar biological medicinal products \u2012 Scientific guideline. Accessed 16.12.2024.  https:\/\/www.ema.europa.eu\/en\/similar-biological-medicinal-products-scientific-guideline"},{"key":"key-10.17116\/oftalma2025141021106-7","unstructured":"U.S. Congress. U.S. Code, Chapter 6A, Subchapter II, Part F, Subpart 1, Section \u00a7 262. Regulation of biological products. Legal Information Institute, Cornell Law School. 2010 March 23. Accessed 04.02.2025.  https:\/\/www.law.cornell.edu\/uscode\/text\/42\/262"},{"key":"key-10.17116\/oftalma2025141021106-8","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00715-y"},{"key":"key-10.17116\/oftalma2025141021106-9","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(13)70145-1"},{"key":"key-10.17116\/oftalma2025141021106-10","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000003626"},{"key":"key-10.17116\/oftalma2025141021106-11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.343"},{"key":"key-10.17116\/oftalma2025141021106-12","unstructured":"Ivanov R, Sekareva G, Kravtsova O, Kudlai D, Lukyanov S, Tikhonova I, Demin A, Maksumova L, Nikitina I, Obukhov A, Zaitsev D, Stepanov A, Nosyreva M, Samsonov M. Guidelines of research biosimilar drugs. Farmakokinetika i farmakodinamika. 2014;1:21-36 (In Russ.)"},{"key":"key-10.17116\/oftalma2025141021106-13","unstructured":"Resolution of the Government of the Russian Federation of September 5, 2020 No. 1360 \u00abOn the procedure for determining the interchangeability of drugs for medical use\u00bb. Accessed 06.02.2025 (In Russ.). https:\/\/base.garant.ru\/74614808\/?ysclid=m8g6z8zhtv868124574"},{"key":"key-10.17116\/oftalma2025141021106-14","unstructured":"Considerations in demonstrating interchangeability with a reference product. Guidance for industry. 2019. Accessed 07.02.2025.  https:\/\/www.fda.gov\/media\/124907\/download"},{"key":"key-10.17116\/oftalma2025141021106-15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.4557"},{"key":"key-10.17116\/oftalma2025141021106-16","unstructured":"Biosimilar Products. Guideline for the quality, safety and efficacy of follow-on biological medicinal products issued by Ministry of Health, Labour and Welfare, Govermment of Japan. Accessed 16.12.2024.  https:\/\/www.jga.gr.jp\/english\/country-overview\/biosimilar-products.html"},{"key":"key-10.17116\/oftalma2025141021106-17","unstructured":"FDA: Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. Posted on November 20, 2020. Accessed 16.12.2024.  https:\/\/www.regulations.gov\/document\/FDA-2011-D-0611-0081"},{"key":"key-10.17116\/oftalma2025141021106-18","unstructured":"FDA: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2020. Accessed 16.12.2024.  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product"},{"key":"key-10.17116\/oftalma2025141021106-19","unstructured":"U.S. Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product, Guidance for Industry. Official Website of the U.S. Food and Drug Administration. 2015 April 30 [cited: 2020 June 5]. Accessed 16.12.2024.  https:\/\/www.fda.gov\/media\/135612\/download"},{"key":"key-10.17116\/oftalma2025141021106-20","unstructured":"U.S. Food and Drug Administration. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product: Guidance Document. Official Website of the U.S. Food and Drug Administration. 2016 December 29 [cited: 2020 May 20]. Accessed 16.12.2024.  https:\/\/www.fda.gov\/regulatory-information\/searchfda-guidance-documents\/clinical-pharmacology-data-supportdemonstration-biosimilarity-reference-product"},{"key":"key-10.17116\/oftalma2025141021106-21","unstructured":"Ritemvia: European Public Assessment Report \u2012 Scientific Discussion. Official Website of European Medicenes Agency. 2017 August 15 [cited: 2020 May 21]. Accessed 16.12.2024.  https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ritemvia-epar-public-assessment-report_en.pdf"},{"key":"key-10.17116\/oftalma2025141021106-22","unstructured":"European Medicines Agency. Draft guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) \u2012 Revision 1. Official website of European Medicines Agency. 2018 August 15 [cited: 2020 July 19]. Accessed 16.12.2024.  https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-similar-biological-medicinalproducts-containing-recombinant-granulocyte-colony_en.pdf"},{"key":"key-10.17116\/oftalma2025141021106-23","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000242842.14624.e7"},{"key":"key-10.17116\/oftalma2025141021106-24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084433"},{"key":"key-10.17116\/oftalma2025141021106-25","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.723"},{"key":"key-10.17116\/oftalma2025141021106-26","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.66"},{"key":"key-10.17116\/oftalma2025141021106-27","unstructured":"FDA Approval History: Lucentis (ranibizumab). Accessed 16.12.2024.  https:\/\/www.drugs.com\/history\/lucentis.html"},{"key":"key-10.17116\/oftalma2025141021106-28","unstructured":"Reestr OHLP i LV EAES FGBU \u00abNCESMP\u00bb Minzdrava Rossii. Obshchaya harakteristika preparata Lucentis. Accessed 03.04.2025 (In Russ.). https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC"},{"key":"key-10.17116\/oftalma2025141021106-29","unstructured":"Reestr OHLP i LV EAES FGBU \u00abNCESMP\u00bb Minzdrava Rossii. Obshchaya harakteristika preparata Laksolan. Accessed 03.04.2025 (In Russ.). https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC"},{"key":"key-10.17116\/oftalma2025141021106-30","unstructured":"Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. EMA\/627319\/2022. Accessed 07.02.2025.  https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf"},{"key":"key-10.17116\/oftalma2025141021106-31","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00488-w"},{"key":"key-10.17116\/oftalma2025141021106-32","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17165800"},{"key":"key-10.17116\/oftalma2025141021106-33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.876503"},{"key":"key-10.17116\/oftalma2025141021106-34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034183"},{"key":"key-10.17116\/oftalma2025141021106-35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd015804.pub2"},{"key":"key-10.17116\/oftalma2025141021106-36","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s457303"},{"key":"key-10.17116\/oftalma2025141021106-37","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-00228-7"},{"key":"key-10.17116\/oftalma2025141021106-38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.031"},{"key":"key-10.17116\/oftalma2025141021106-39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.5053"},{"key":"key-10.17116\/oftalma2025141021106-40","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S307746"},{"key":"key-10.17116\/oftalma2025141021106-41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275611"},{"key":"key-10.17116\/oftalma2025141021106-42","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.ijo_2118_21"},{"key":"key-10.17116\/oftalma2025141021106-43","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.05.005"},{"key":"key-10.17116\/oftalma2025141021106-44","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S407219"},{"key":"key-10.17116\/oftalma2025141021106-45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001205"},{"key":"key-10.17116\/oftalma2025141021106-46","unstructured":"Biosimilar medicines: Overview (EMA). 2017. Accessed 16.12.2024.  https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/biosimilar-medicines-overview"},{"key":"key-10.17116\/oftalma2025141021106-47","unstructured":"Biosimilar Product Information (FDA). 2024. Accessed 16.12.2024.  https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"key-10.17116\/oftalma2025141021106-48","unstructured":"Amgen Releases 8th Edition of Biosimilar Trends Report. Accessed 16.12.2024.  https:\/\/www.amgen.com\/newsroom\/press-releases\/2021\/09\/amgen-releases-8th-edition-of-biosimilar-trends-report"},{"key":"key-10.17116\/oftalma2025141021106-49","unstructured":"Razreshenie na provedenie KI RBS-AMD-III. Accessed 16.12.2024 (In Russ.). https:\/\/clinline.ru\/reestr-klinicheskih-issledovanij\/345-21.07.2020.html"},{"key":"key-10.17116\/oftalma2025141021106-50","unstructured":"Gosudarstvennyi reestr predel\u2019nykh otpusknykh tsen. Accessed 06.02.2025 (In Russ.). https:\/\/grls.minzdrav.gov.ru\/pricelims.aspx"}],"container-title":["Russian Annals of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:59:33Z","timestamp":1747051173000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-oftalmologii\/2025\/2\/10042465X2025021106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5,12]]}},"alternative-id":["10.17116\/oftalma2025141021106"],"URL":"https:\/\/doi.org\/10.17116\/oftalma2025141021106","relation":{},"ISSN":["0042-465X"],"issn-type":[{"value":"0042-465X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}